Glatiramer Acetate
A deliberately random mixture of four amino acids, approved for multiple sclerosis for thirty years
Glatiramer acetate is not one peptide but a mixture of synthetic polypeptides of random length and sequence, built from four amino acids in fixed proportions. It has reduced relapses in multiple sclerosis since 1996, and carries a boxed warning for anaphylaxis that can occur years into treatment.
What is it?
Glatiramer is unusual among approved drugs: no two molecules in a vial are necessarily identical. It is made by polymerising four amino acids in a fixed molar ratio to random lengths, and the mixture as a whole is the drug. Its mechanism is immunological and not fully settled; studies in treated patients describe a shift in the kind of immune response rather than suppression of it.
The founding trial in 1995 and its extensions established a roughly 29% reduction in relapse rate, and the comparisons since have mostly been against interferon beta rather than placebo. A network meta-analysis found the interferons and glatiramer each beat placebo but not one another. The original trial's participants have now been followed for up to 27 years, and those who started early took about three years longer to reach confirmed disability worsening than those who started later.
The Copaxone label gives two strengths that are explicitly not interchangeable: 20 mg/mL once a day, or 40 mg/mL three times a week at least 48 hours apart, subcutaneously only. Patients on the three-times-weekly dose reported more satisfaction and adherence. Its pharmacokinetics section says a substantial fraction of each dose is hydrolysed at the injection site, which is why there is no blood level to speak of.
Generics followed, and a switching study found no loss of control after moving from the brand. The next step is less frequent dosing: a long-acting depot cut relapses by 30% against placebo in a 1,016-patient phase 3 trial, at the cost of more injection-site reactions. In secondary progressive disease, neither it nor rituximab stopped disability worsening in a small trial.
The boxed warning is the part worth knowing: life-threatening and fatal anaphylaxis has been reported, and it can happen at any time, from the first dose to years into treatment.
Mechanism of Action
Glatiramer is a random polymer of four amino acids that shifts the immune response in multiple sclerosis rather than suppressing it.
A mixture, not a molecule
Glutamic acid, lysine, alanine and tyrosine polymerised in a fixed ratio to random lengths.
Immune shift
Studies in treated patients describe a change in the kind of T-cell response rather than broad suppression.
Local breakdown
A substantial fraction of each dose is hydrolysed at the injection site (label 12.3).
Published Research
These are the trials in people, read from their PubMed abstracts, with dosing and the boxed warning from the Copaxone label read on October 1, 2026.
The trial it was approved on
In a multicentre phase 3 trial, 251 patients with relapsing-remitting multiple sclerosis received 20 mg daily by subcutaneous injection or placebo for two years. The two-year relapse rate was 1.19 against 1.68, a 29% reduction (p = 0.007), with trends favouring the drug on the proportion relapse-free and time to first relapse.
It held up over longer use
An extension study found continued use of glatiramer acetate was well tolerated and maintained its clinical effect beyond the original trial period.
Against interferon beta
In an open-label comparison in 58 patients followed for two years against their own preceding two years, glatiramer acetate and interferon beta-1b were compared on relapse rate, disability accumulation and safety.
What it does to the immune response
A study of Th17 immune responses in patients with multiple sclerosis treated with glatiramer acetate, part of the body of work describing a shift in immune response type rather than general suppression.
The response it induces
In treated patients, glatiramer acetate induced degenerate, Th2-polarised immune responses, which is the mechanistic account the drug's development rests on.
27 years: early against delayed start
In the open-label extension of the original US trial, 208 participants were followed up to 27 years; those who started glatiramer early took longer to reach confirmed disability worsening than those who started 2 to 3 years later (9.8 against 6.7 years for 6-month confirmed worsening).
Three times weekly against daily
In 857 patients, the 40 mg/mL three-times-weekly dose gave higher treatment satisfaction, convenience and adherence than 20 mg/mL daily, with no new safety findings.
Switching to a generic
In the GATE extension, patients switched from branded to generic glatiramer had relapse rates (0.24 against 0.21), MRI activity, adverse events and antibody titres similar to those kept on the generic throughout.
A monthly depot
In a phase 3 trial of 1,016 patients, GA Depot, a long-acting injectable glatiramer, lowered the annualised relapse rate by 30.1% against placebo (0.18 against 0.26) and reduced enhancing lesions; injection-site reactions occurred in 46.1% against 28.7%.
Secondary progressive disease
In 73 patients with secondary progressive multiple sclerosis, disability worsened over the trial on both rituximab and glatiramer, with no significant difference between them.
Against the interferons
A network meta-analysis of 24 studies found glatiramer and the beta-interferons all lowered relapse rate against placebo but did not differ from each other, with similar discontinuation for adverse events.
Dosing Data
Copaxone is injected under the skin either 20 mg every day or 40 mg three times a week at least 48 hours apart; the two strengths are not interchangeable.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Side Effects & Contraindications
Reported Side Effects
From the Copaxone label (SPL version 36, effective June 23, 2026).
Contraindications & Cautions
From the label.
Legal Status
An approved drug of long standing, now also generic.
Frequently Asked Questions
?What is glatiramer acetate?
A mixture of synthetic polypeptides of random sequence and length, made from glutamic acid, lysine, alanine and tyrosine in fixed proportions. The mixture is the drug.
?How well does it work?
In its two-year approval trial it cut the relapse rate by 29% against placebo in relapsing-remitting multiple sclerosis.
?What is the dosing?
The label gives 20 mg/mL once daily or 40 mg/mL three times a week at least 48 hours apart, subcutaneously. The two strengths are not interchangeable.
?What is the boxed warning?
Life-threatening and fatal anaphylaxis, which can occur at any point from the first dose to years into treatment.
?Can I switch between the 20 mg and 40 mg versions?
Not as a simple swap: the label says the two strengths are not interchangeable. One is given daily and the other three times a week at least 48 hours apart, so a switch is a prescriber's decision.
?Does a generic work as well?
In the GATE extension, patients moved from the brand to a generic had similar relapse rates, MRI activity and side effects to those kept on the generic throughout.
References
- [fda-pi] Copaxone (glatiramer acetate) prescribing information, boxed warning and sections 1, 2, 4 and 12.3 (DailyMed SPL version 36, effective June 23, 2026; read October 1, 2026).
- [pubmed] Johnson KP, et al. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group." Neurology, 1995;45(7):1268-76. PMID: 7617181.
- [pubmed] Johnson KP, et al. "Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group." Neurology, 1998;50(3):701-8. PMID: 9521260.
- [pubmed] Flechter S, et al. "Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up." J Neurol Sci, 2002;197(1-2):51-5. PMID: 11997066.
- [pubmed] Melnikov M, et al. "The influence of glatiramer acetate on Th17-immune response in multiple sclerosis." PLoS One, 2020;15(10):e0240305. PMID: 33126239.
- [pubmed] Duda PW, et al. "Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis." J Clin Invest, 2000;105(7):967-76. PMID: 10749576.
- [pubmed] Ford CC, et al. "Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study." Mult Scler, 2022;28(11):1729-1743. PMID: 35768939.
- [pubmed] Melendez-Torres GJ, et al. "Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages." BMC Neurol, 2018;18(1):162. PMID: 30285675.
- [clinical-trial] Cutter G, et al. "Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS." Mult Scler Relat Disord, 2019;33:13-21. PMID: 31132664.
- [clinical-trial] Selmaj K, et al. "Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results." Mult Scler, 2017;23(14):1909-1917. PMID: 28090798.
- [clinical-trial] Miller A, et al. "GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial." Mult Scler, 2026;32(2):202-213. PMID: 41705515.
- [clinical-trial] Cheshmavar M, et al. "Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial." Acta Neurol Scand, 2021;143(2):178-187. PMID: 32897569.
- [fda-pi] Copaxone (glatiramer acetate injection) US prescribing information (DailyMed set aa88f583, effective June 23, 2026), sections 2.1-2.2; read through openFDA October 6, 2026.
Sources & Citations
Studies were read from their PubMed abstracts; the Copaxone label from DailyMed (set aa88f583, effective June 23, 2026) through openFDA, read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.